Grifols, S.A.
Grifols, S.A. (GRFS) Stock Competitors & Peer Comparison
See (GRFS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRFS | $9.10 | -3.60% | 8B | 14.46 | $0.65 | +1.52% |
| LLY | $1,053.92 | +3.00% | 952.9B | 43.99 | $22.96 | +0.62% |
| AZN | $205.51 | -0.46% | 633.8B | 31.30 | $6.53 | +1.82% |
| JNJ | $245.51 | -0.57% | 584.4B | 22.01 | $11.02 | +2.10% |
| ABBV | $228.77 | +1.97% | 397.6B | 95.32 | $2.36 | +2.94% |
| NVS | $164.76 | +0.51% | 314.5B | 22.78 | $7.14 | +2.01% |
| MRK | $123.65 | +1.46% | 305.4B | 16.80 | $7.28 | +2.68% |
| NVO | $39.90 | -17.66% | 210.9B | 12.96 | $3.66 | +2.59% |
| AMGN | $381.36 | +1.56% | 202B | 26.34 | $14.23 | +2.58% |
| GILD | $149.92 | -0.79% | 187.8B | 18.58 | $8.15 | +2.09% |
Stock Comparison
GRFS vs LLY Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, LLY has a market cap of 952.9B. Regarding current trading prices, GRFS is priced at $9.10, while LLY trades at $1,053.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas LLY's P/E ratio is 43.99. In terms of profitability, GRFS's ROE is +0.07%, compared to LLY's ROE of +0.98%. Regarding short-term risk, GRFS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check LLY's competition here
GRFS vs AZN Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, AZN has a market cap of 633.8B. Regarding current trading prices, GRFS is priced at $9.10, while AZN trades at $205.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas AZN's P/E ratio is 31.30. In terms of profitability, GRFS's ROE is +0.07%, compared to AZN's ROE of +0.23%. Regarding short-term risk, GRFS is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check AZN's competition here
GRFS vs JNJ Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, JNJ has a market cap of 584.4B. Regarding current trading prices, GRFS is priced at $9.10, while JNJ trades at $245.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas JNJ's P/E ratio is 22.01. In terms of profitability, GRFS's ROE is +0.07%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, GRFS is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check JNJ's competition here
GRFS vs ABBV Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, ABBV has a market cap of 397.6B. Regarding current trading prices, GRFS is priced at $9.10, while ABBV trades at $228.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas ABBV's P/E ratio is 95.32. In terms of profitability, GRFS's ROE is +0.07%, compared to ABBV's ROE of -4.22%. Regarding short-term risk, GRFS is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check ABBV's competition here
GRFS vs NVS Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, NVS has a market cap of 314.5B. Regarding current trading prices, GRFS is priced at $9.10, while NVS trades at $164.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas NVS's P/E ratio is 22.78. In terms of profitability, GRFS's ROE is +0.07%, compared to NVS's ROE of +0.33%. Regarding short-term risk, GRFS is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check NVS's competition here
GRFS vs MRK Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, MRK has a market cap of 305.4B. Regarding current trading prices, GRFS is priced at $9.10, while MRK trades at $123.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas MRK's P/E ratio is 16.80. In terms of profitability, GRFS's ROE is +0.07%, compared to MRK's ROE of +0.36%. Regarding short-term risk, GRFS is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check MRK's competition here
GRFS vs NVO Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, NVO has a market cap of 210.9B. Regarding current trading prices, GRFS is priced at $9.10, while NVO trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas NVO's P/E ratio is 12.96. In terms of profitability, GRFS's ROE is +0.07%, compared to NVO's ROE of +0.61%. Regarding short-term risk, GRFS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check NVO's competition here
GRFS vs AMGN Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, AMGN has a market cap of 202B. Regarding current trading prices, GRFS is priced at $9.10, while AMGN trades at $381.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas AMGN's P/E ratio is 26.34. In terms of profitability, GRFS's ROE is +0.07%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, GRFS is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check AMGN's competition here
GRFS vs GILD Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, GILD has a market cap of 187.8B. Regarding current trading prices, GRFS is priced at $9.10, while GILD trades at $149.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas GILD's P/E ratio is 18.58. In terms of profitability, GRFS's ROE is +0.07%, compared to GILD's ROE of +0.41%. Regarding short-term risk, GRFS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check GILD's competition here
GRFS vs PFE Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, PFE has a market cap of 151.6B. Regarding current trading prices, GRFS is priced at $9.10, while PFE trades at $27.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas PFE's P/E ratio is 19.60. In terms of profitability, GRFS's ROE is +0.07%, compared to PFE's ROE of +0.09%. Regarding short-term risk, GRFS is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check PFE's competition here
GRFS vs BMY Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, BMY has a market cap of 123.6B. Regarding current trading prices, GRFS is priced at $9.10, while BMY trades at $61.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas BMY's P/E ratio is 17.54. In terms of profitability, GRFS's ROE is +0.07%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GRFS is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check BMY's competition here
GRFS vs GSK Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, GSK has a market cap of 120.1B. Regarding current trading prices, GRFS is priced at $9.10, while GSK trades at $59.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas GSK's P/E ratio is 15.75. In terms of profitability, GRFS's ROE is +0.07%, compared to GSK's ROE of +0.30%. Regarding short-term risk, GRFS is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check GSK's competition here
GRFS vs SNY Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, SNY has a market cap of 113.6B. Regarding current trading prices, GRFS is priced at $9.10, while SNY trades at $47.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas SNY's P/E ratio is 19.48. In terms of profitability, GRFS's ROE is +0.07%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GRFS is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check SNY's competition here
GRFS vs BIIB Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, BIIB has a market cap of 28.2B. Regarding current trading prices, GRFS is priced at $9.10, while BIIB trades at $195.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas BIIB's P/E ratio is 21.85. In terms of profitability, GRFS's ROE is +0.07%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, GRFS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check BIIB's competition here
GRFS vs HZNP Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GRFS is priced at $9.10, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GRFS's ROE is +0.07%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GRFS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check HZNP's competition here
GRFS vs OGN Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, OGN has a market cap of 2.1B. Regarding current trading prices, GRFS is priced at $9.10, while OGN trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas OGN's P/E ratio is 11.25. In terms of profitability, GRFS's ROE is +0.07%, compared to OGN's ROE of +0.24%. Regarding short-term risk, GRFS is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check OGN's competition here
GRFS vs CELG-RI Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, CELG-RI has a market cap of 163.3M. Regarding current trading prices, GRFS is priced at $9.10, while CELG-RI trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.07%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, GRFS is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check CELG-RI's competition here
GRFS vs CTOR Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, CTOR has a market cap of 102.4M. Regarding current trading prices, GRFS is priced at $9.10, while CTOR trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas CTOR's P/E ratio is -3.74. In terms of profitability, GRFS's ROE is +0.07%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, GRFS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check CTOR's competition here
GRFS vs SCLX Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, SCLX has a market cap of 69.4M. Regarding current trading prices, GRFS is priced at $9.10, while SCLX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas SCLX's P/E ratio is -0.20. In terms of profitability, GRFS's ROE is +0.07%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, GRFS is more volatile compared to SCLX. This indicates potentially higher risk in terms of short-term price fluctuations for GRFS.Check SCLX's competition here
GRFS vs MIRA Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, MIRA has a market cap of 49.8M. Regarding current trading prices, GRFS is priced at $9.10, while MIRA trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas MIRA's P/E ratio is -0.74. In terms of profitability, GRFS's ROE is +0.07%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, GRFS is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check MIRA's competition here
GRFS vs SRXH Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, SRXH has a market cap of 4.3M. Regarding current trading prices, GRFS is priced at $9.10, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas SRXH's P/E ratio is -0.75. In terms of profitability, GRFS's ROE is +0.07%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, GRFS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check SRXH's competition here
GRFS vs SCLXW Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, GRFS is priced at $9.10, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.07%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, GRFS is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check SCLXW's competition here
GRFS vs BDSIW Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GRFS is priced at $9.10, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GRFS's ROE is +0.07%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GRFS is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check BDSIW's competition here
GRFS vs CRXT Comparison February 2026
GRFS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRFS stands at 8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GRFS is priced at $9.10, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRFS currently has a P/E ratio of 14.46, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GRFS's ROE is +0.07%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GRFS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GRFS.Check CRXT's competition here